Atlas Trials

Dinutuximab and Irinotecan Versus Irinotecan to Treat Subjects With Relapsed or Refractory Small Cell Lung Cancer

Clinical trial NCT03098030 · COMPLETED

Trial details

NCT number
NCT03098030
Sponsor
United Therapeutics
Status
COMPLETED
Phase
Phase 2, Phase 3
Study type
INTERVENTIONAL
Small Cell Lung Cancer
Start date
2017-06-01
Primary completion
2020-01-27
Enrollment
483

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.